---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-013781"
form_type: "8-K"
ticker: "RNXT"
cik: "0001574094"
company_name: "RenovoRx, Inc."
filed_at: "2023-04-27T23:59:59+00:00"
generated_at: "2026-06-16T08:57:36.522772+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# RenovoRx appoints former Schering-Plough CMO Robert Spiegel to board

## Summary
- Dr. Spiegel appointed as independent director effective April 25, 2023; board size increased from 6 to 7.
- He brings 40+ years biopharma experience, involved in over 30 FDA NDA approvals and multiple blockbuster drugs.
- Received initial option award for 43,026 shares valued at $120,000, vesting monthly over 36 months.
- Company plans to advance FDA discussions on RenovoGem Phase III interim data and new indications.
- Dr. Spiegel also serves on boards of Geron, Cyclacel, Ayala, Athenex, and SPARC.

## SEC filing metadata
- accession: 0001493152-23-013781
- form_type: 8-K
- ticker: RNXT
- cik: 0001574094
- company_name: RenovoRx, Inc.
- filed_at: 2023-04-27T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574094/000149315223013781/0001493152-23-013781-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574094/000149315223013781/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-013781
- JSON: https://secwatch.observer/filing/0001493152-23-013781.json
- Plain text: https://secwatch.observer/filing/0001493152-23-013781.txt

## Key facts
- Executive change
  Robert Spiegel was appointed as independent director at RenovoRx, Inc..
  - Action: appointed
  - Role: independent director
  source text: Effective as of April 25, 2023, the Board of Directors of RenovoRx, Inc. (the “Company”) appointed Robert Spiegel, M.D., FACP, to its Board of Directors as an independent director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1574094/000149315223013781/0001493152-23-013781-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.